Clinical Trials Browser

ilorasertib × Clear all

Neoplasm Metastasis

NCT02540876 2019-04-22

Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

Phase 1 Completed

12 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01110473 2017-11-20

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

Phase 1 Completed

52 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01110486 2013-11-06

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Phase 1 Completed

102 enrolled

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors